That current oncology drugs on USA market have the universal problems about low effectiveness of pharmacology to cancer cells and high risk of toxicology to normal cells can demonstrate following most significantly and most reasonably: it is not enough so far away that just only oncology drug target molecules as cancer patient-specific biomarkers directly; it must be that oncology drug targets' SNPs like as real personalized or individualized cancer patient-specific biomarkers.